CLDX
Price
$27.81
Change
+$1.14 (+4.27%)
Updated
Dec 3 closing price
Capitalization
1.85B
88 days until earnings call
Intraday BUY SELL Signals
PGEN
Price
$3.57
Change
+$0.09 (+2.59%)
Updated
Dec 3 closing price
Capitalization
1.26B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs PGEN

Header iconCLDX vs PGEN Comparison
Open Charts CLDX vs PGENBanner chart's image
Celldex Therapeutics
Price$27.81
Change+$1.14 (+4.27%)
Volume$804.54K
Capitalization1.85B
Precigen
Price$3.57
Change+$0.09 (+2.59%)
Volume$2.62M
Capitalization1.26B
CLDX vs PGEN Comparison Chart in %
View a ticker or compare two or three
VS
CLDX vs. PGEN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (CLDX: $26.66 vs. PGEN: $3.49)
Brand notoriety: CLDX and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 37% vs. PGEN: 30%
Market capitalization -- CLDX: $1.85B vs. PGEN: $1.26B
CLDX [@Biotechnology] is valued at $1.85B. PGEN’s [@Biotechnology] market capitalization is $1.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLDX and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 7 TA indicator(s) are bullish while PGEN’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 7 bullish, 3 bearish.
  • PGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than PGEN.

Price Growth

CLDX (@Biotechnology) experienced а +0.83% price change this week, while PGEN (@Biotechnology) price change was -4.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 02, 2026.

PGEN is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.85B) has a higher market cap than PGEN($1.26B). PGEN YTD gains are higher at: 211.607 vs. CLDX (5.501). PGEN has higher annual earnings (EBITDA): -121.98M vs. CLDX (-231.4M). CLDX has more cash in the bank: 630M vs. PGEN (59.8M). CLDX has less debt than PGEN: CLDX (3.03M) vs PGEN (5.15M). CLDX has higher revenues than PGEN: CLDX (5.79M) vs PGEN (4.34M).
CLDXPGENCLDX / PGEN
Capitalization1.85B1.26B146%
EBITDA-231.4M-121.98M190%
Gain YTD5.501211.6073%
P/E RatioN/AN/A-
Revenue5.79M4.34M133%
Total Cash630M59.8M1,054%
Total Debt3.03M5.15M59%
FUNDAMENTALS RATINGS
CLDX vs PGEN: Fundamental Ratings
CLDX
PGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4435
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3885

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (69) in the Biotechnology industry is in the same range as PGEN (75) in the null industry. This means that CLDX’s stock grew similarly to PGEN’s over the last 12 months.

CLDX's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CLDX’s stock grew similarly to PGEN’s over the last 12 months.

CLDX's SMR Rating (96) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CLDX’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (35) in the null industry is in the same range as CLDX (44) in the Biotechnology industry. This means that PGEN’s stock grew similarly to CLDX’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as CLDX (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXPGEN
RSI
ODDS (%)
Bullish Trend 7 days ago
83%
Bearish Trend 7 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
81%
Bullish Trend 7 days ago
89%
Momentum
ODDS (%)
Bullish Trend 7 days ago
82%
Bearish Trend 7 days ago
87%
MACD
ODDS (%)
Bullish Trend 7 days ago
85%
Bearish Trend 7 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
80%
Bearish Trend 7 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
78%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
75%
Bearish Trend 7 days ago
88%
Aroon
ODDS (%)
Bearish Trend 7 days ago
85%
Bullish Trend 7 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signal:
Gain/Loss:
PGEN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANVIX28.70N/A
N/A
Virtus NFJ Large-Cap Value Fund Inst
DDIIX16.22N/A
N/A
Nomura Wealth Builder Institutional
JMGMX56.72N/A
N/A
JPMorgan Mid Cap Growth R6
BREUX41.71N/A
N/A
Baron Real Estate R6
BOSYX20.02N/A
N/A
BNY Mellon Sm Cp Val Y

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+2.85%
BEAM - CLDX
55%
Loosely correlated
-2.83%
XNCR - CLDX
54%
Loosely correlated
-3.15%
KURA - CLDX
53%
Loosely correlated
-2.53%
CRNX - CLDX
53%
Loosely correlated
-0.53%
VRDN - CLDX
52%
Loosely correlated
-3.26%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARRY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-3.32%
ARRY - PGEN
39%
Loosely correlated
-0.13%
VCYT - PGEN
39%
Loosely correlated
-0.43%
AXON - PGEN
38%
Loosely correlated
+0.91%
MRNA - PGEN
38%
Loosely correlated
-0.41%
CLDX - PGEN
38%
Loosely correlated
+2.85%
More